Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Dopamine (DA) transporter (DAT) imaging has been studied as a diagnostic tool for degenerative parkinsonism. Our aim was to measure the prognostic value of imaging for motor and nonmotor outcomes in Parkinson's disease (PD). We prospectively evaluated a Parkinson's cohort after enrollment in a de novo clinical trial with a battery of motor (UPDRS), cognitive (Montreal Cognitive Assessment), and behavioral measures. DAT imaging with [123 I][β]‐CIT and single‐photon emission computerized tomography (SPECT) was performed at baseline and after 22 months. In total, 491 (91%) of the 537 subjects had evidence of DA deficiency on their baseline scan, consistent with PD, and were included in the analyses. The cohort was followed for 5.5 (0.8) years, with a mean duration of diagnosis of 6.3 (1.2). Lower striatal binding at baseline was independently associated with higher risk for clinical milestones and measures of disease severity, including motor‐related disability, falling and postural instability, cognitive impairment, psychosis, and clinically important depressive symptoms. Subjects in the bottom quartile for striatal binding, compared to the top quartile, had an odds ratio (95% confidence interval) of 3.3 (1.7, 6.7) for cognitive impairment and 12.9 (2.6, 62.4) for psychosis. Change from baseline in imaging after 22 months was also independently associated with motor, cognitive, and behavioral outcomes. DAT imaging with [123 I][β]‐CIT and SPECT, shortly after the diagnosis of PD, was independently associated with clinically important long‐term motor and nonmotor outcomes. These results should be treated as hypothesis generating and require confirmation. © 2012 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Dopamine, learning and motivation.
Wise, R. A. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1406 · Cited by 3,379 · cited 1×
“Dopaminergic projections from the tegmental area and substantia nigra modulate the activity of medium spiny neurons, the main output neurons of the striatum, and thereby modulate memory, learning, motivation, and affective control.(24) Three striatal outflow circuits support nonmotor behaviors often affected in PD, in…”
Background(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 4×
“Cohort characteristics at baseline and most recent assessment PreCEPT PostCEPT Baseline* Most Recent Visit N ¼ 491 N ¼ 491 Mean (SD) Mean (SD) Age, years 59.61 (9.43) 65.13 (9.39) Duration of symptoms, years 2.06 (1.38) 7.58 (1.63) Duration since diagnosis, years 0.79 (0.80) 6.31 (1.19) MMSE exam 29.34 (0.99) 28.65 (2…”
ResultInfluentialRole of dopamine in the motivational and cognitive control of behavior
Cools, R. (2008) · The Neuroscientist · doi:10.1177/1073858408317009 · Cited by 352
Cited by
The psychosis spectrum in Parkinson disease
ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.200 · Cited by 355
Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
Verschuur, C. V. M., Suwijn, S. R., Boel, J. A., Post, B., Bloem, B. R., van Hilten, J. J., van Laar, T., Tissingh, G., Munts, A. G., Deuschl, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809983 · Cited by 353
Self-citationMak, E., Su, L., Williams, G. B., Firbank, M. J., Lawson, R. A., Yarnall, A. J., Duncan, G. W., Owen, A. M., Khoo, T. K., Brooks, D. J., et al. (2015) · Brain · doi:10.1093/brain/awv211 · Cited by 260
Lenka, A., Jhunjhunwala, K. R., Saini, J., & Pal, P. K. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.04.005 · Cited by 106
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Metadata
- Authors
- Ravina, B., Marek, K., Eberly, S., Oakes, D., Kurlan, R., Ascherio, A., Beal, F., Beck, J., Flagg, E., Galpern, W. R., Harman, J., Lang, A. E., Schwarzschild, M., Tanner, C., & Shoulson, I.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2012-09-13
- Volume
- 27
- Issue
- 11
- Pages
- 1392-1397
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2075790964
- Cited by
- 133
- References
- 4
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease. https://app.cochat.ai/papers/10.1002/mds.25157
- The paper
- Ravina, B., Marek, K., Eberly, S., Oakes, D., Kurlan, R., Ascherio, A., Beal, F., Beck, J., Flagg, E., Galpern, W. R., Harman, J., Lang, A. E., Schwarzschild, M., Tanner, C., & Shoulson, I. (2012). Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.25157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.